SNGX Soligenix, Inc.

$0.40

Soligenix, Inc. (SNGX) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on August 7, 2026.

Soligenix Beat Consensus Estimates
Friday, August 7, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 7:30 AM ET
Earnings Whisper
-
vs ($0.12)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.39

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Soligenix, Inc.

Soligenix Inc is a clinical stage biopharmaceutical company engaged in developing products to treat serious inflammatory diseases and where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics.

Sector

Healthcare

Industry

Biotechnology